Skip to content

Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)

An Open-label, Controlled, Cross-over Trial of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) in Mild Cognitive Impairment

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01688128
Acronym
U-SMART
Enrollment
50
Registered
2012-09-19
Start date
2012-08-31
Completion date
2015-12-31
Last updated
2016-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Keywords

Mild cognitive impairment, Cognitive rehabilitation, Cognitive therapy, Spaced retrieval Training, Alzheimer's disease, Memory enhancement, U-healthcare

Brief summary

The purpose of this study is to examine the efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (U-SMART) in the elderly individuals with mild cognitive impairment (MCI) by an open-label, controlled, crossover Trial.

Detailed description

The Spaced Retrieval-based Memory Advancement and Rehabilitation Training (SMART) which consisted of 24 one-hour face-to-face sessions (Lee, Park et al. 2009) was developed based on the spaced retrieval training (SRT), which was effective in improving memory retention span of very mild to mild Alzheimer's disease patients. The Ubiquitous SMART (U-SMART) by transforming the current SMART to a self-administered program using an application working on IPAD was developed, and showed its feasibility and efficacy in the elderly individuals with mild cognitive impairment in the preliminary study. (ClinicalTrials.gov ID: NCT01628653) To validate the efficacy of the U-SMART, an open-label, controlled, crossover design of clinical trial were planned in this study.

Interventions

DEVICEPhase I U-SMART (4 wks)

Intervention\_Control Group, 4-weeks U-SMART(2 session/week); Control\_Intervention Group, no intervention

OTHERWashout (2 wks)

2-weeks wash out period in both arms

DEVICEPhase II U-SMART (4 wks)

Intervention\_Control Group, no intervention; Control\_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)

Sponsors

KT Corporation
CollaboratorINDUSTRY
Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Aged 55-90 * Educational level above 1 year and confirmed literacy * Diagnosed to mild cognitive impairment by International Working Group on Mild Cognitive Impairment * Clinical Dementia Rating (CDR) of 0 or 0.5

Exclusion criteria

* Diagnosed to dementia by DSM-IV * Evidence of delirium, confusion * Any neurological conditions causing cognitive decline such as Parkinson's disease, brain hemorrhage, brain tumor, normal pressure hydrocephalus * Evidence of severe cerebrovascular pathology * History of loss-of-consciousness over 1 hour due to head trauma or repetitive head trauma of mild severity * History of substance abuse or dependence such as alcohol * Presence of depressive symptoms that could influence cognitive function * Presence of medical comorbidities that could result in cognitive decline Use of medication that could influence cognitive function seriously

Design outcomes

Primary

MeasureTime frameDescription
Change in the Word List Test (memory, recall, recognition) of the CERAD Neuropsychological Assessment Battery before and after phase I intervention and before and after phase II intervention (crossover part of the study)Baseline, 5 weeks, 11weeksTo evaluate the efficacy of the U-SMART, the Word List Memory Test (WLMT), Word List Recall Test (WLRT), Word List Recognition Test (WLRcT) of the CERAD neuropsychological assessment battery were applied to all participants.

Secondary

MeasureTime frameDescription
Change in the Subjective Memory Complaints Questionnaire (SMCQ) before and after phase I intervention and before and after phase II intervention (crossover part of the study)Baseline, 5 weeks, 11weeksTo evaluate the subjective memory improvement after the U-SMART, the Subjective Memory Complaints Questionnaire(SMCQ) was applied to all participants.
Change in the Geriatric Depression Scale (GDS) before and after phase I intervention and before and after phase II intervention (crossover part of the study)Baseline, 5 weeks, 11weeksTo evaluate the subjective mood after the U-SMART, the Geriatric Depression Scale was applied to all participants.
Change in the Mini-Mental State Examination before and after phase I intervention and before and after phase II intervention (crossover part of the study)Baseline, 5 weeks, 11weeksTo evaluate the global cognitive function after the U-SMART, the Mini-Mental State Examination was applied to all participants.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026